Dr. Matthew Lederman is a board-certified Reproductive Endocrinologist and Infertility Specialist, and is often acknowledged for his compassionate care, devotion to patients and his clinical expertise. He treats patients in New York City at the RMA of NY Westside location as well as in the RMA Westchester office in White Plains. Prior to joining RMA of NY in 2014, Dr. Lederman treated patients at the Continuum Reproductive Center at St. Luke’s Roosevelt Hospital Center.

After graduating from the University of Michigan, Dr. Lederman received his medical degree from the Chicago Medical School and completed his residency in Obstetrics and Gynecology as well as his fellowship in Reproductive Endocrinology and Infertility at the Albert Einstein College of Medicine/Montefiore Medical Center. During his residency, he served as administrative chief resident and also received the Albert Einstein College of Medicine of Yeshiva University Teaching Award two years in a row. While in fellowship, Dr. Lederman was acknowledged by the Endocrine Society for his research and received a travel grant.

He serves on the Medical Advisory Board of FORCE: Facing our Risk of Cancer Empowered, the Scientific Advisory Board for TEAL: Tell Every Amazing Lady About Ovarian Cancer and, is a fellow of the American College of Obstetricians and Gynecologists. He is a member of the American Society for Reproductive Medicine, Society of Reproductive Endocrinology and Infertility, Endocrine Society, Westchester OB/GYN Society, and Resolve. He was also named to the list of SuperDoctors featured in New York Times Magazine consistently since 2015 in their New York Edition.

Dr. Lederman has published scientific abstracts and articles in peer-reviewed journals in the fields of endocrinology and infertility, and has presented his research at national conferences. He has extensive clinical experience in all areas of fertility, including unexplained infertility, recurrent pregnancy loss, in vitro fertilization, egg freezing, pre-implantation genetic screening and fertility preservation for patients recently diagnosed with cancer (oncofertility) and those who are pre-disposed to hereditary cancer syndromes (ie. BRCA).